Thorax
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial.
Alexander G Mathioudakis, Sebastian Bate, Victoria Chatzimavridou-Grigoriadou, Pradeesh Sivapalan, Jens-Ulrik Stæhr Jensen, Nawar Diar Bakerly, Jørgen Vestbo, Dave Singh
Published: 202510.1136/thorax-2025-223282
Abstract
BACKGROUND: In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment discontinuations. Discontinuing inhaled corticosteroids (ICS) can trigger withdrawal effects transiently increasing exacerbation risk…
Preview only. Read the full abstract at the source